Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GYS-016 adjunctive host-directed therapy in rifampicin-resistant/multidrug-resistant pulmonary tuberculosis
ChiCTR2600121616Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of auranofin in pulmonary tuberculosis (TB) and Tuberculosis (TB) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Sputum Acid-Fast Bacilli (AFB) smear, Sputum Mycobacterium tuberculosis culture and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
auranofin
03
Conditions
pulmonary tuberculosis (TB)Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2600121616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121616.